U.S. Transthyretin Amyloidosis Treatment Market Size & Outlook
U.S. transthyretin amyloidosis treatment market, 2018-2030 (US$M)
Related Markets
U.S. transthyretin amyloidosis treatment market highlights
- The U.S. transthyretin amyloidosis treatment market generated a revenue of USD 2,899.1 million in 2024 and is expected to reach USD 7,427.0 million by 2030.
- The U.S. market is expected to grow at a CAGR of 14.4% from 2025 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2024.
- Targeted Therapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Transthyretin amyloidosis treatment market data book summary
| Market revenue in 2024 | USD 2,899.1 million |
| Market revenue in 2030 | USD 7,427.0 million |
| Growth rate | 14.4% (CAGR from 2025 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Targeted Therapy |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Targeted Therapy, Supportive Therapy |
| Key market players worldwide | Pfizer Inc, Johnson & Johnson, Ionis Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Astellas Pharma Inc, Prothena Corp PLC, Acrotech BioPharma, SOM Biotech |
Other key industry trends
- In terms of revenue, U.S. accounted for 43.6% of the global transthyretin amyloidosis treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. transthyretin amyloidosis treatment market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 7,427.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Transthyretin Amyloidosis Treatment Market Scope
Transthyretin Amyloidosis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. transthyretin amyloidosis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to transthyretin amyloidosis treatment market will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 117.1% in 2024. Horizon Databook has segmented the U.S. transthyretin amyloidosis treatment market based on targeted therapy, supportive therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. transthyretin amyloidosis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. transthyretin amyloidosis treatment market databook
-
Our clientele includes a mix of transthyretin amyloidosis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. transthyretin amyloidosis treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. transthyretin amyloidosis treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. transthyretin amyloidosis treatment market size, by therapy, 2018-2030 (US$M)
U.S. Transthyretin Amyloidosis Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
